JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on February 1, 2005; DOI: 10.1124/jpet.104.081612


0022-3565/05/3133-1118-1125$20.00
JPET 313:1118-1125, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.081612v1
313/3/1118    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Licata, S. C.
Right arrow Articles by Rowlett, J. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Licata, S. C.
Right arrow Articles by Rowlett, J. K.

BEHAVIORAL PHARMACOLOGY

Contribution of GABAA Receptor Subtypes to the Anxiolytic-Like, Motor, and Discriminative Stimulus Effects of Benzodiazepines: Studies with the Functionally Selective Ligand SL651498 [6-Fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1H-pyridol[3,4-b]indol-1-one]

Stephanie C. Licata, Donna M. Platt, James M. Cook, P. V. V. Srirama Sarma, Guy Griebel, and James K. Rowlett

Harvard Medical School, New England Primate Research Center, Southborough, Massachusetts (S.C.L., D.M.P., J.K.R.); University of Wisconsin-Milwaukee, Milwaukee, Wisconsin (J.M.C., P.V.V.S.S.); and Central Nervous System Research Department, Sanofi-Aventis, Bagneux, France (G.G.)

Benzodiazepines (BZs) are prescribed for a variety of disorders, including those involving anxiety and sleep, but have unwanted side effects that limit their use. Elucidating the GABAA receptor mechanisms underlying the behavioral effects of BZs will help develop new drugs having both maximum clinical benefit and minimum adverse side effects. A recently developed compound is SL651498 [6-fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1H-pyridol[3,4-b]indol-1-one], which is a full agonist at GABAA receptors containing {alpha}2and {alpha}3 subunits and a partial agonist at GABAA receptors containing {alpha}1 and {alpha}5 subunits. We assessed the ability of SL651498 to engender anxiolytic-like, motor, and subjective effects characteristic of BZ-type drugs in nonhuman primates. Anxiolytic-like activity was assessed with a conflict procedure in rhesus monkeys. Motor effects were evaluated in squirrel monkeys using observational techniques, and the subjective effects of SL651498 were assessed in squirrel monkeys trained to discriminate the nonselective BZ triazolam from saline. SL651498 engendered anxiolytic-like effects similar to conventional BZs. In addition, SL651498 fully induced muscle relaxation, but unlike conventional BZs, engendered minimal ataxia. In drug discrimination studies, SL651498 partially substituted for triazolam. This effect was blocked with the {alpha}1 GABAA subtype-preferring antagonist {beta}-CCT ({beta}-carboline-3-carboxylate-t-butyl ester), implicating {alpha}1 GABAA effects receptors in the subjective of SL651498. Together, these studies suggest that compounds such as SL651498 that have high intrinsic efficacy at {alpha}2GABAA and/or {alpha}3GABAA receptors may have clinical potential as anxiolytics and muscle relaxants. Moreover, a compound with reduced efficacy at {alpha}1 GABAA and/or {alpha}5 GABAA receptors may lack some of the motor and subjective effects associated with conventional BZs.


Received December 3, 2004; accepted January 31, 2005.

Address correspondence to: Dr. Stephanie C. Licata, One Pine Hill Drive, P.O. Box 9102, Southborough, MA 01772. E-mail: stephanie_licata{at}hms.harvard.edu




This article has been cited by other articles:


Home page
J PsychopharmacolHome page
S.L. de Haas, S.J. de Visser, J.P. van der Post, R.C. Schoemaker, K. van Dyck, M.G. Murphy, M. de Smet, L.K. Vessey, R. Ramakrishnan, L. Xue, et al.
Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABAA {alpha}2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers
J Psychopharmacol, January 1, 2008; 22(1): 24 - 32.
[Abstract] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
L. P. Carter, R. R. Griffiths, P. E. Suess, J. H. Casada, C. L. Wallace, and J. D. Roache
Relative Abuse Liability of Indiplon and Triazolam in Humans: A Comparison of Psychomotor, Subjective, and Cognitive Effects
J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 749 - 759.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
N. R. Mirza, R. J. Rodgers, and L. S. Mathiasen
Comparative Cue Generalization Profiles of L-838, 417, SL651498, Zolpidem, CL218,872, Ocinaplon, Bretazenil, Zopiclone, and Various Benzodiazepines in Chlordiazepoxide and Zolpidem Drug Discrimination
J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1291 - 1299.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.